Cool perfusion solutions for skin flaps: a new mixture of pharmacological agents which improves skin flap viability.
This study tested the hypotheses that perfusion of cooled skin flaps with established organ preservation solutions improves their viability and that this improvement can be further enhanced by pharmacological manipulation. Rabbit epigastric skin flaps were perfused with different solutions before explantation and stored at 8 degrees C for 6 days. In the first part of the experiment, flap viability was assessed 7 days after reperfusion of the flap via microvascular anastomoses. The different solutions were heparinised blood, University of Wisconsin solution, two of its modifications, EuroCollins solution and a pharmacological mixture containing phosphoenolpyruvate, desferrioxamine, nitrendipine, dextran 70 and a platelet-aggregating factor receptor antagonist (WEB 2170). In the second part, biochemical parameters of skin were measured at various reperfusion times. Adenosine triphosphate (ATP), reduced glutathione (GSH), myeloperoxidase (MPO) and tissue water were assayed at 0, 1, and 24 h after reperfusion. In addition, plasma thromboxane (TXB2) was measured at 0, 30 and 60 minutes after reperfusion. The viability of flaps perfused with the mixture (81%) was significantly higher than that of any of the other groups (39% for controls, 38% for EuroCollins, 13% for UW solution, 27% and 31% for its modifications). ATP levels after reperfusion were higher in the mixture group than in UW-perfused group. GSH levels in the mixture group were also higher than in the UW group, indicating higher level of protection against oxidative stress during reperfusion. There were no differences in MPO levels. Thromboxane levels associated with UW-perfused flaps were significantly higher than those associated with any other perfusion solution. In conclusion, perfusion of a mixture of pharmacological agents targeting specific aspects of ischaemia/reperfusion injury improved the viability of skin flaps stored in the cold for 6 days, whereas standard organ preservation solutions failed to affect significantly skin flap survival.
Kohout
M
M
Microsurgery Research Centre, St. Vincent's Hospital, Melbourne, Australia.
Lepore
D A
DA
Knight
K R
KR
Van Gelder
J
J
O'Brien
B M
BM
Stewart
A G
AG
Morrison
W A
WA
D000241:Adenosine; D000255:Adenosine Triphosphate / Q000032:analysis; D000493:Allopurinol; D000818:Animals; D003080:Cold Temperature; D005260:Female; D005978:Glutathione / Q000032:analysis; D006085:Graft Survival / Q000187:drug effects*; D006982:Hypertonic Solutions; D007328:Insulin; D008297:Male; D019188:Organ Preservation Solutions; D009195:Peroxidase / Q000032:analysis; D011817:Rabbits; D011887:Raffinose; D012867:Skin / Q000737:chemistry; D013524:Surgical Flaps; D013929:Thromboxane B2 / Q000032:analysis; D013997:Time Factors; D014021:Tissue Preservation / Q000379:methods*
C037096:Euro-Collins' solution; D006982:Hypertonic Solutions; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D013929:Thromboxane B2; D000493:Allopurinol; D000255:Adenosine Triphosphate; D009195:Peroxidase; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose